Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978

Cullinan Therapeutics, Inc.

HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).
CLN-978 is a CD19xCD3 bispecific T cell engager designed for off-the-shelf access and convenient dosing.
SLE affects ~430,000 people globally; current treatments rarely induce treatment-free remission.
Company also submitted IND to U.S. FDA for this study on September 16, 2024.
Trial will assess safety, pharmacokinetics, and initial clinical activity in multiple countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.